Cidara Therapeutics (CDTX) Projected to Post Earnings on Thursday

Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) is expected to post its Q1 2025 quarterly earnings results after the market closes on Thursday, May 8th. Analysts expect the company to announce earnings of ($5.45) per share for the quarter.

Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) last released its earnings results on Thursday, March 6th. The biotechnology company reported ($5.38) earnings per share for the quarter, missing the consensus estimate of ($5.28) by ($0.10). Cidara Therapeutics had a negative return on equity of 69.64% and a negative net margin of 289.05%. On average, analysts expect Cidara Therapeutics to post $-9 EPS for the current fiscal year and $-14 EPS for the next fiscal year.

Cidara Therapeutics Stock Down 7.2 %

Shares of Cidara Therapeutics stock traded down $1.54 on Tuesday, reaching $19.96. 31,515 shares of the stock were exchanged, compared to its average volume of 71,586. Cidara Therapeutics has a twelve month low of $10.14 and a twelve month high of $28.42. The business has a 50 day moving average price of $20.93 and a two-hundred day moving average price of $20.20. The firm has a market capitalization of $250.44 million, a price-to-earnings ratio of -0.79 and a beta of 0.86.

Wall Street Analysts Forecast Growth

CDTX has been the subject of several recent analyst reports. StockNews.com raised shares of Cidara Therapeutics to a "sell" rating in a report on Wednesday, April 16th. Needham & Company LLC reissued a "buy" rating and issued a $35.00 price target on shares of Cidara Therapeutics in a research note on Thursday, April 10th. Citizens Jmp began coverage on shares of Cidara Therapeutics in a research report on Wednesday, March 12th. They set an "outperform" rating and a $46.00 price target for the company. Citigroup began coverage on Cidara Therapeutics in a research note on Wednesday, March 12th. They set an "outperform" rating on the stock. Finally, HC Wainwright boosted their price target on shares of Cidara Therapeutics from $24.00 to $35.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $39.14.

Insider Buying and Selling

In related news, COO Shane Ward sold 1,664 shares of Cidara Therapeutics stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $21.96, for a total value of $36,541.44. Following the transaction, the chief operating officer now owns 14,674 shares in the company, valued at approximately $322,241.04. This trade represents a 10.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Leslie Tari sold 1,773 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $21.96, for a total transaction of $38,935.08. Following the sale, the insider now directly owns 16,215 shares of the company's stock, valued at approximately $356,081.40. This trade represents a 9.86 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.64% of the company's stock.

About Cidara Therapeutics

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.